3 completed, 3 recruiting, 1 not yet recruiting. 4 Phase 2, 1 Not applicable, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 2, Recruiting 2 |
| Not applicable | 1 | Not yet recruiting 1 |
| Phase 1 | 1 | Recruiting 1 |
| Phase 3 | 1 | Completed 1 |
Follow Relapsed Peripheral T-Cell Lymphoma: new trials by email Literature Review of Relapsed Peripheral T-Cell Lymphoma trials Research Report on Relapsed Peripheral T-Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pralatrexate Combined With Chidamide Bridging Allogeneic HSCT for Refractory/Relapsed Peripheral T-cell Lymphoma Pralatrexate combined with Chidamide bridging Allogeneic Hematopoietic Stem Cell Transplantation - Relapsed Peripheral T-Cell Lymphoma, Refractory Peripheral T-Cell Lymphoma | Not applicable | Not yet recruiting | Peking University People's Hospital | 25 | 2024-12-01 | 2024-11-06 |
| Pembrolizumab and Olaparib Treatment for Relapsed or Refractory Peripheral T-Cell Lymphoma Pembrolizumab IV infusion Q3W, with daily oral Olaparib. - Relapsed Peripheral T-Cell Lymphoma, Refractory Peripheral T-Cell Lymphoma | Phase 2 | Recruiting | National Cancer Centre, Singapore | 24 | 2024-07-01 | 2025-09-05 |
| Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma Biopsy, Biospecimen Collection, Bone Marrow Biopsy - Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma | Phase 1 | Recruiting | Mayo Clinic | 21 | 2024-01-05 | 2026-07-01 |
| Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma Chidamide combined with Duvillisib - Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma | Phase 2 | Recruiting | The First Affiliated Hospital of Xiamen University | 33 | 2023-11-22 | 2025-02-19 |
| Study of Brentuximab Vedotin in Patients With R/R PTCL Treated With Gemcitabine Brentuximab Vedotin - induction, Gemcitabine, Brentuximab Vedotin - maintenance - Refractory Peripheral T-Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma | Phase 2 | Completed | The Lymphoma Academic Research Organisation | 71 | 2018-04-10 | 2025-07-30 |
| Phase II Study of Folotyn With Leucovorin to Prevent/Reduce Mucositis in Patients With Hematological Malignancies Folotyn and Leucovorin, Folic Acid, Vitamin B12 - Relapsed Peripheral T-Cell Lymphoma, Refractory Peripheral T-Cell Lymphoma | Phase 2 | Completed | Acrotech Biopharma Inc. | 36 | 2014-07-01 | 2019-11-20 |
| Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma Alisertib, Pralatrexate, Gemcitabine - Relapsed Peripheral T-Cell Lymphoma, Refractory Peripheral T-Cell Lymphoma | Phase 3 | Completed | Millennium Pharmaceuticals, Inc. | 271 | 2012-06-11 | 2018-07-31 |
Lymphoma, T-Cell, Peripheral (7) · Lymphoma, T-Cell (3) · Lymphoma, Large-Cell, Anaplastic (1) · Mycosis Fungoides (1)
Hemic and Lymphatic Diseases (7) · Immune System Diseases (7) · Immunoproliferative Disorders (7) · Lymphatic Diseases (7) · Lymphoma (7) · Lymphoma, Non-Hodgkin (7) · Lymphoproliferative Disorders (7) · Neoplasms (7) · Neoplasms by Histologic Type (7) · Lymphoma, T-Cell (4) · Lymphoma, T-Cell, Cutaneous (1)
10-propargyl-10-deazaaminopterin (2) · Gemcitabine (2) · Biopsy (1) · Brentuximab Vedotin (1) · Disulfides (1) · Folic Acid (1) · Immunoglobulin G (1) · Leucovorin (1) · MLN 8237 (1) · Magnetic Resonance Spectroscopy (1) · Photons (1) · Specimen Handling (1) · Vitamin B 12 (1) · X-Rays (1) · cemiplimab (1)
Acrotech Biopharma Inc. (1) · Mayo Clinic (1) · Millennium Pharmaceuticals, Inc. (1) · National Cancer Centre, Singapore (1) · Peking University People's Hospital (1) · The First Affiliated Hospital of Xiamen University (1) · The Lymphoma Academic Research Organisation (1)
United States (3) · Belgium (2) · China (2) · France (2) · Australia (1) · Austria (1) · Belarus (1) · Brazil (1) · Bulgaria (1) · Canada (1) · Chile (1) · Czechia (1) · Denmark (1) · Egypt (1) · Germany (1)
Bing Xu (1) · Jason YS Chan, MBBS, MRCP, MMed, FAMS, PhD (1) · Kah Whye Peng, PhD (1) · Nora Bennani, MD (1) · Wasim Khan, MD (1) · Xiaodong Mo (1)
PMID 30707661, PMID 35175355, PMID 40546726, PMID 40758949
P50CA186781 (1), R01CA262613 (1)